CBIO
HealthcareCrescent Biopharma, Inc. · Biotechnology · $570M
What is Crescent Biopharma, Inc.?
Crescent Biopharma is a clinical-stage biotechnology company focused on developing cancer therapies. Headquartered in Waltham, Massachusetts, the company is building a pipeline of oncology candidates targeting solid tumors.
Crescent Biopharma researches and develops cancer therapy candidates, with its lead program targeting solid tumors through a bispecific antibody approach. The company generates no product revenue at this stage, relying instead on its strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to advance and potentially commercialize its oncology pipeline.
Crescent Biopharma was founded in 2014 and is based in Waltham, Massachusetts.
- CR-001: anti-PD-1/anti-VEGF bispecific antibody for solid tumors
- CR-002 oncology candidate
- CR-003 oncology candidate
- Strategic oncology partnership with Sichuan Kelun-Biotech
Is CBIO a Good Stock to Buy?
UQS Score rates CBIO as Poor overall, reflecting the early-stage nature and current profile of the business.
Among the five pillars, Risk stands out as the relative bright spot — a notable distinction for a pre-revenue biotech. This suggests the company's balance sheet or near-term financial exposure is managed more carefully than many peers at a similar stage.
Quality, Moat, and Growth all register as Weak, which is typical for a pipeline-stage company without approved products or recurring revenue. Valuation is rated Elevated, meaning the market may already be pricing in optimistic outcomes.
See the full pillar breakdown and financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CBIO pay dividends?
No — Crescent Biopharma, Inc. does not currently pay a dividend.
Crescent Biopharma does not pay a dividend, which is standard for clinical-stage biotechs. All available capital is directed toward research, development, and advancing the oncology pipeline. Income-focused investors should look elsewhere; CBIO is structured around long-term pipeline value rather than near-term shareholder distributions.
When does CBIO report earnings?
Crescent Biopharma reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue biotech, quarterly reports focus on pipeline progress, cash runway, and operating expenses rather than sales or profit metrics. Key updates typically cover clinical trial milestones and partnership developments.
For the most recent quarter's results, visit Crescent Biopharma's investor relations page directly.
CBIO Price History
-90.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Crescent Biopharma, Inc.?
Based on Crescent Biopharma, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CBIO Long-term Outlook
With Growth and Quality both rated Weak, the near-term fundamental outlook for CBIO depends heavily on clinical trial readouts rather than organic business momentum. The Elevated Valuation rating suggests the current price reflects considerable optimism about pipeline success. The Good Risk rating provides some reassurance about financial stability, but the path to value creation remains contingent on development milestones.
Growth drivers
- Advancement of CR-001 through clinical trials for solid tumors
- Expanded collaboration with Sichuan Kelun-Biotech on novel oncology combinations
- Potential pipeline broadening via CR-002 and CR-003 programs
Key risks
- Clinical trial failure or delays across the oncology pipeline
- Elevated valuation leaving limited margin of safety if milestones slip
- Dependence on partnership and external funding in the absence of product revenue
CBIO vs Peers
Crescent Biopharma operates in a crowded small-cap biotech space alongside other clinical-stage companies pursuing specialty therapeutic areas.
Palatin focuses on melanocortin system therapeutics, differentiating itself from CBIO's oncology-centered bispecific antibody approach.
Prothena targets neurodegeneration and rare diseases, giving it a distinct therapeutic focus compared to Crescent's solid tumor pipeline.
Rigel has a commercial-stage product in hematology/oncology, placing it further along the development curve than CBIO.
Frequently Asked Questions
What does Crescent Biopharma do?
Crescent Biopharma is a clinical-stage biotechnology company developing cancer therapies. Its lead candidate, CR-001, is a bispecific antibody designed to treat solid tumors. The company also has two additional oncology candidates in its pipeline and a strategic partnership with Sichuan Kelun-Biotech to advance and commercialize its programs.
Does CBIO pay dividends?
No, Crescent Biopharma does not pay a dividend. As a pre-revenue biotech, the company reinvests all available capital into research and clinical development. Dividend income is not part of the CBIO investment thesis at this stage.
When does CBIO report earnings?
Crescent Biopharma reports on a quarterly cadence, standard for US-listed public companies. Because the company has no product revenue, reports center on pipeline updates and cash position. Check the company's investor relations page for the latest schedule and filings.
Is CBIO a good stock to buy?
UQS Score rates CBIO as Poor overall. Quality, Moat, and Growth are all Weak, while Valuation is Elevated — a combination that warrants careful consideration. The Good Risk rating is a relative positive. Investors should review the full pillar breakdown available to UQS Pro members before drawing conclusions.
Is CBIO overvalued?
UQS Score's Valuation pillar for CBIO is rated Elevated, suggesting the market price may already reflect optimistic assumptions about pipeline outcomes. For a pre-revenue biotech, this means there is limited margin of safety if clinical milestones are delayed or missed.
How does CBIO compare to its competitors?
Compared to peers like Rigel Pharmaceuticals, which has a commercial product, CBIO is at an earlier development stage. Palatin Technologies and Prothena focus on different therapeutic areas entirely. CBIO's differentiation lies in its bispecific antibody approach to solid tumors and its Kelun-Biotech partnership.
What is CBIO's market cap bracket?
Crescent Biopharma is classified as a small-cap stock. This places it in a segment of the market characterized by higher volatility and greater sensitivity to clinical trial outcomes compared to large- or mega-cap healthcare companies.
Who founded Crescent Biopharma?
Crescent Biopharma was founded in 2014. For detailed founding history and leadership background, the company's official website and SEC filings are the most reliable sources of information.
Is CBIO a long-term quality investment?
As a long-term quality indicator, UQS Score rates CBIO as Poor, with Weak scores across Quality, Moat, and Growth pillars. Long-term value creation depends on successful clinical development and eventual commercialization — outcomes that remain uncertain at this stage. Pro members can access the complete analysis.
What is the main competitive advantage of Crescent Biopharma?
Crescent Biopharma's potential edge lies in its proprietary bispecific antibody technology targeting solid tumors and its partnership with Sichuan Kelun-Biotech, which provides access to novel oncology combinations. However, the UQS Moat pillar is currently rated Weak, reflecting the early and unproven nature of these advantages.
Unlock Full CBIO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings for CBIO
- ✓Access detailed financial metrics and trend data
- ✓Compare CBIO side-by-side with competitors using UQS pillar scores
- ✓Screen for higher-quality biotech alternatives across the healthcare sector
- ✓Get the complete risk and valuation breakdown in one place
Pro Analysis
CBIO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 16.4 | 2.1 | 10.0 | 18.8 | 64.2 | 0.0 | +0.5 |
| May 8, 2026 | 15.9 | 0.0 | 10.0 | 18.8 | 64.2 | 0.0 | -0.5 |
| May 7, 2026 | 16.4 | 2.1 | 10.0 | 18.8 | 64.2 | 0.0 | -3.6 |
| May 3, 2026 | 20.0 | 1.7 | 10.0 | 37.5 | 64.2 | 0.0 | -0.2 |
| May 1, 2026 | 20.2 | 1.7 | 10.0 | 37.5 | 64.9 | 0.0 | +0.5 |
| Apr 2, 2026 | 19.7 | 1.7 | 10.0 | 37.5 | 61.8 | 0.0 | — |
CBIO — Pillar Breakdown
Quality
— 2.1/100 (25%)Crescent Biopharma, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 18.8/100 (20%)Crescent Biopharma, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 64.2/100 (15%)Crescent Biopharma, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Crescent Biopharma, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 10/100 (25%)Crescent Biopharma, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CBIO.
Score Composition
Financial Data
More Stock Analysis
How is the CBIO UQS Score Calculated?
The UQS (Unified Quality Score) for Crescent Biopharma, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Crescent Biopharma, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Crescent Biopharma, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.